Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOEL M GELFAND

Allopathic & Osteopathic Physicians Dermatology

NPI
1710902382
CMS profile
349563
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$88,357.27

65 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $19,915.51 22
UCB SA $16,073.37 4
Boehringer Ingelheim Pharmaceuticals, Inc. $15,745.91 5
E.R. Squibb & Sons, L.L.C. $7,250.00 5
Amgen Inc. $6,613.85 8
Lilly USA, LLC $5,505.00 4
Boehringer Ingelheim International GmbH $3,944.66 2
LEO Pharma Inc. $3,560.00 1
NOVARTIS PHARMACEUTICALS CORPORATION $3,373.45 7
Janssen Biotech, Inc. $3,150.52 4
GlaxoSmithKline, LLC. $1,950.00 2
Mindera Corp $1,275.00 1

Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOEL M GELFAND

NPI 1710902382 · CMS profile ID 349563

Allopathic & Osteopathic Physicians / Dermatology

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1710902382?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOEL M GELFAND, NPI 1710902382, CMS profile ID 349563. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710902382?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JOEL M GELFAND, NPI 1710902382, CMS profile ID 349563. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710902382?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JOEL M GELFAND, NPI 1710902382, CMS profile ID 349563, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1710902382?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

65 matching records · $88,357.27 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 65 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–65 of 65.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $6.5703/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939189731 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $6.5703/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965472053 CMS
ABBVIE INC. $19.4503/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920378517 CMS
Amgen Inc. $20.5203/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939189729 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $20.5203/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965472017 CMS
GlaxoSmithKline, LLC. $1,300.0003/15/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944756847 CMS
ABBVIE INC. $1,700.0002/28/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891017193 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $7,450.0002/15/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887511341 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $2,235.0002/15/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887511343 CMS
Lilly USA, LLC $5,400.0002/01/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918094401 CMS
Lilly USA, LLC $35.0001/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918084977 CMS
Lilly USA, LLC $25.0001/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918089391 CMS
Lilly USA, LLC $45.0001/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918135759 CMS
Mindera Corp $1,275.0001/26/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963855261 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $100.9101/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887511337 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $136,507.09 27
PY2020 $82,430.88 52
PY2021 $96,461.51 37
PY2022 $88,357.27 65
PY2023 $94,480.05 103
PY2024 $84,610.45 114
PY2025 $65,986.59 50

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $21,487.50 5
PY2024 Recipient $16,500.00 4
PY2024 Principal investigator $38,641.21 1
PY2023 Principal investigator $5,580.00 1
PY2022 Principal investigator $671,012.72 6
PY2021 Principal investigator $77,696.00 2
PY2020 Recipient $6,587.91 2
PY2020 Principal investigator $1,009,521.45 2
PY2019 Recipient $1,292.76 1
PY2019 Principal investigator $1,198,139.74 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

5 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Takeda Pharmaceuticals U.S.A., Inc. $5,400.00 12/19/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262912
Recipient Takeda Pharmaceuticals U.S.A., Inc. $4,800.00 09/18/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262910
Recipient Teva Pharmaceuticals USA, Inc. $3,412.50 09/04/2025 Covered Recipient Physician A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244051955
Recipient Teva Pharmaceuticals USA, Inc. $4,875.00 05/02/2025 Covered Recipient Physician A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244051953
Recipient Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 03/07/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262908